JACC Heart Failure Editor's Update, February 2019
FEBRUARY 2018 MINI-FOCUS ISSUE: CARDIAC CONSQUENCES OF NON-CARDIAC DISEASE
The heart and liver are closely related and cardiohepatic interactions are complex. Impairment of cardiac function may lead to hepatic dysfunction and vice versa. Andrew Xanthopoulos and colleagues review the pathophysiology, characteristics, and clinical significance of the interaction of heart failure and liver disease, including heart failure after liver transplantation and a look at the promising area of research into the gut microbiota–liver interaction in heart failure. Click below to learn more:
Heart Failure and Liver Disease: Cardiohepatic Interactions
Andrew Xanthopoulos, Randall C. Starling, et al
HIV patients have nearly twice the risk for cardiac dysfunction, a topic of increasing relevance as patients with HIV are living longer. New treatments have brought about longer survival for patients with HIV and a concomitant increase in the prevalence of chronic diseases including cardiovascular disease. Sebhal Erqou et. al. present a review and meta-analysis of studies of heart failure and other cardiac dysfunction among patients living with HIV to facilitate interpretation of the data and guide future research. Click below to read more:
Cardiac Dysfunction Among People Living With HIV: A Systematic Review and Meta-Analysis
Sebhat Erqou, Bereket Tessema Lodebo, et al
Important new data from the GUIDE IT Echo Substudy: does lowering natriuretic peptides in HFrEF patients reflect structural and functional changes in the heart? Through the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Echo Substudy, Melissa Daubert and colleagues looked at remodeling indices and clinical outcomes in patients receiving NT-ProBNP-guided treatment versus usual care to determine if biomarker guided therapy could help improve clinical outcomes. Read below:
NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF
Melissa A. Daubert, Kirkwood Adams, et al
Orly Vardeny and Muthiah Vaduganathan provide guidance for cardiologists on initiating and monitoring treatment with SGLT2 inhibitors. Despite studies that have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the rate of hospitalization for heart failure in diabetic patients, very few at risk patients are prescribed these drugs and fewer than 5% of prescriptions are written by cardiologists. Mechanisms, benefits and cautions associated with this therapy are presented and discussed. Read below:
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
Orly Vardeny and Muthiah Vaduganathan
MEET EXECUTIVE EDITOR: Mona Fiuzat
Mona Fiuzat’s in-depth knowledge of pharmacology, heart failure research and clinical trials adds an important perspective to our discussions, and her outstanding organizational ability keeps our editorial meetings and publication schedule on track.
Mona Fiuzat, PharmD, FACC, FHFA, FHFSA, is an Associate Professor of Medicine at Duke University, Senior Scientific Advisor at the FDA, Executive Editor of JACC: Heart Failure, and Former Senior Scientific Advisor to the FDA Commissioner. She received her PharmD at Mercer University School of Pharmacy in Atlanta, Georgia, and has worked in clinical trials for over 20 years. Dr. Fiuzat worked in the pharmaceutical industry for Solvay Pharmaceuticals and SmithKline Beecham Pharmaceuticals, and was Director of Clinical Development at ARCA biopharma, Inc. Her clinical research experience has been in cardiovascular trials with a focus on pharmacogenetics in heart failure, and she helped file an NDA for the first proposed pharmacogenetically targeted heart failure drug. She worked as a Clinical Pharmacist at the West Los Angeles and San Francisco Veterans Affairs Medical Center, and as an Adjunct Assistant Professor at the University of Southern California, University of California, San Francisco, University of Colorado, and University of North Carolina. She worked in the Heart Failure Research Program at Duke on a number of key clinical trials as an investigator and steering committee member, and has authored or co-authored over 100 papers in the field of heart failure. Most recently, she developed and facilitated the “Heart Failure Collaboratory”, a joint effort of government agencies, academicians, stakeholders, patients, societies and advocacy groups to impact heart failure research and therapeutic development. She holds national leadership roles with the American College of Cardiology (ACC), and as former Program Co-Chair for the Heart Failure Society of America’s (HFSA) Scientific Sessions, as well as former Membership Co-Chair. She now serves on the HFSA Board of Directors and Executive Committee, HFSA Research Network Task Force, Chair of the HFSA Patient Engagement Initiative, ACC Education and Outcomes Committee, AHA Nominations Committee, and FDA liaison to the HFSA. She is the 2019 recipient of the ACC Distinguished Associate Award.
3 Things People May Not Know about Me:
- I have an intense love for college football, and the Clemson Tigers in particular. This was my year of glory when we beat Alabama 44-14 in the national championship (we were 20-point underdogs).
- In my younger days, I played the drums and piano, so I can complete the JACC HF band (S3 gallopers) with Mike Felker, Jim Januzzi and Hector Ventura.
- I don’t have a middle name, so when I was young, I adopted the middle name “Christine” after my favorite Charlie’s Angel. All my childhood toys have the initials “MCF” on them.
NEW JOURNAL FEATURE
I am also excited to announce a new feature for Original Research papers. Due to the popularity of our Central Illustrations in State-of-the-Art papers, JACC: Heart Failure will now include a Central Illustration for all New Research Papers. The Central Illustration summarizes the main point of the manuscript or a major section of the manuscript. One of the Figures of the manuscript may be designated. We hope you enjoy this additional special feature of the journal! For more information, see below:
All Original Research Papers and State-of-the-Art Reviews must develop 1 Central Illustration, which summarizes the main point of the manuscript or at least a major section of the manuscript. If one of the Figures already provided in your manuscript is a key figure summarizing the major findings, you may designate that figure as the Central Illustration in the legend. The figure may incorporate multiple panels including key figures or graphics, or short text lists summarizing key points or variables. The purpose of these illustrations is to provide a snapshot of your paper in a single visual, conceptual manner. This illustration must be accompanied by a legend (title and caption). The Central Illustration must be an original image and, for copyright reasons, cannot be adapted or reprinted from another source.